Yield10 Bioscience (Yield10 Bioscience) EBIT : $-13.06 Mil (TTM As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience EBIT?

Yield10 Bioscience's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-2.44 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.06 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Yield10 Bioscience's annualized ROC % for the quarter that ended in Mar. 2024 was -190.96%. Yield10 Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -462.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Yield10 Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -504.72%.

Yield10 Bioscience EBIT Historical Data

The historical data trend for Yield10 Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yield10 Bioscience EBIT Chart

Yield10 Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-8.60

-9.61

-11.69

-13.45

-14.42

Yield10 Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-3.80	-3.67	-3.70	-3.25	-2.44

Competitive Comparison of Yield10 Bioscience's EBIT

For the Agricultural Inputs subindustry, Yield10 Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yield10 Bioscience's EV-to-EBIT Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's EV-to-EBIT falls into.

Yield10 Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.06 Mil.

Yield10 Bioscience (OTCPK:YTEN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Yield10 Bioscience's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-9.76 * ( 1 - 0% )	/	( (4.29	+	5.932)	/ 2 )
=	-9.76	/	5.111
=	-190.96 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.907	-	3.082	-	( 1.068	-	max(0, 4.865	-	1.4	+	1.068	))
=	4.29

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.243	-	2.398	-	( 1.597	-	max(0, 6.21	-	2.123	+	1.597	))
=	5.932

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Yield10 Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-9.76	/	( ( (2.201 + max(-2.853, 0))	+	(2.016 + max(-4.003, 0)) )	/	2 )
=	-9.76	/	( ( 2.201	+	2.016 )	/	2 )
=	-9.76	/	2.1085
=	-462.89 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.332)	-	(3.082	+	0	+	0.103)
=	-2.853

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.526)	-	(2.398	+	1.7	+	0.431)
=	-4.003

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Yield10 Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-13.057	/	2.587
	=	-504.72 %

Yield10 Bioscience EBIT Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Yield10 Bioscience (Yield10 Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (OTCPK:YTEN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

M6X3:Germany

Address

19 Presidential Way, Woburn, MA, USA, 01801

Website

https://www.yield10bio.com

Yield10 Bioscience Inc is an agricultural bioscience company. It focuses on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. The company uses two proprietary advanced biotechnology trait gene discovery platforms to improve fundamental crop yield through enhanced photosynthetic carbon capture and increased carbon utilization efficiency to increase seed yield. Having developed various crops, such as Camelina, canola, soybean, and corn, the firm concentrates to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton	director	1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser	officer: VP Fin and CAO
Lynne H Brum	officer: VP Planning and Comms	21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell	officer: VP Research & CSO	C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey	director	C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown	director	C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples	director, officer: Pres & CEO	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin	director	21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully	10 percent owner	C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038